T3D4552

4606 T3D4552

Eszopiclone

Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia. Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones. Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia. 138729-47-2

969472

C17H17ClN6O3

White powder.

very slightly soluble

Rapidly absorbed following oral administration

The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes.

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. Route of Elimination: Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites. Half Life: 6 hours No indication of carcinogenicity to humans (not listed by IARC).

For the treatment of insomnia

Side effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses.

2014-08-30T21:03:31Z

2014-12-24T20:26:52Z

Eszopiclone

53760

DB00402

true

[H][C@@]1(OC(=O)N2CCN(C)CC2)N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1

C17H17ClN6O3

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1

InChIKey=GBBSUAFBMRNDJC-INIZCTEOSA-N

388.808

388.105066147

Exogenous Solid 0.8

CHEMBL1522

839530

Marioara MENDELOVICI, Anita LIBERMAN, Alex MAINFELD, Nina FINKELSTEIN, “METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE.” U.S. Patent US20070270590, issued November 22, 2007.